HIV-associated psoriasis: pathogenesis, clinical features, and management

The Lancet Infectious Diseases

Volumn 10, Issue 7, 2010, Pages 470-478

  Morar, Nilesh ^a   Willis Owen, Saffron A ^b   Maurer, Toby ^c   Bunker, Christopher B ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CIMETIDINE; CIPROFLOXACIN; COAL TAR; CORTICOSTEROID; CYCLOSPORIN A; DITHRANOL; EMOLLIENT AGENT; ENFUVIRTIDE; ETANERCEPT; ETRETIN; GAMMA INTERFERON; HYDROXYUREA; INDINAVIR; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 23; KETOCONAZOLE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEVIRAPINE; PENICILLIN G; RIFAMPICIN; RITONAVIR PLUS SAQUINAVIR; STAVUDINE; TAZAROTENE; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; ZIDOVUDINE;

ALOPECIA; AUTOIMMUNITY; BACTERIAL INFECTION; BETA HEMOLYTIC STREPTOCOCCUS; BIOLOGICAL THERAPY; CANDIDIASIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEILITIS; COMORBIDITY; CONDYLOMA LATUM; CYTOMEGALOVIRUS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ERYTHEMA; ERYTHRODERMA; GENETIC PREDISPOSITION; HAIRY LEUKOPLAKIA; HERPES SIMPLEX VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PARVOVIRUS B19; HYPERKERATOSIS; HYPERTENSION; ICHTHYOSIS; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNOMODULATION; LEUKOPENIA; LIPOATROPHY; LIVER TOXICITY; LOW DRUG DOSE; MORTALITY; NAIL DYSTROPHY; NEPHROTOXICITY; NONHUMAN; ONYCHOLYSIS; ONYCHOMYCOSIS; OPPORTUNISTIC INFECTION; PARONYCHIA; PATHOGENESIS; PHENOTYPIC VARIATION; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; PUVA; REITER SYNDROME; REVIEW; SCABIES; SECONDARY SYPHILIS; SOUTH AFRICA; SYSTEMIC THERAPY; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TREATMENT RESPONSE; UNITED STATES; VARICELLA ZOSTER VIRUS; XEROSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV INFECTIONS; HUMANS; PSORIASIS; SKIN DISEASES;

EID: 77953648234     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70101-8     Document Type: Review

References (111)

1. UNAIDS, and WHO. AIDS epidemic update 2009 (2009), Joint United Nations Programme on HIV/AIDS and World Health Organization, Geneva
2. HPA. HIV in the United Kingdom: 2008 report (2008), Health Protection Agency, London
3. Bowcock A.M., and Cookson W.O. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet 13 (2004) R43-R55
4. Gladman D.D., and Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs 9 (2000) 1511-1522
5. Lowes M.A., Bowcock A.M., and Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 445 (2007) 866-873
6. Lebwohl M. Psoriasis. Lancet 361 (2003) 1197-1204
7. Trembath R.C., Clough R.L., Rosbotham J.L., et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 6 (1997) 813-820
8. Bowcock A.M., and Krueger J.G. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 5 (2005) 699-711
9. Tiilikainen A., Lassus A., Karvonen J., Vartiainen P., and Julin M. Psoriasis and HLA-Cw6. Br J Dermatol 102 (1980) 179-184
10. Mallon E., Bunce M., Savoie H., et al. HLA-C and guttate psoriasis. Br J Dermatol 143 (2000) 1177-1182
11. Lew W., Bowcock A.M., and Krueger J.G. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol 25 (2004) 295-305
12. Griffiths C.E., and Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 370 (2007) 263-271
13. Sugiyama H., Gyulai R., Toichi E., et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 174 (2005) 164-173
14. Heidenreich R., Rocken M., and Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 90 (2009) 232-248
15. Bhushan M., McLaughlin B., Weiss J.B., and Griffiths C.E. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141 (1999) 1054-1060
16. McFadden J., Valdimarsson H., and Fry L. Cross-reactivity between streptococcal M surface antigen and human skin. Br J Dermatol 125 (1991) 443-447
17. Wiemers S., Krutmann J., Kapp A., and Schopf E. Postherpetic erythema exsudativum multiforme with concomitant exacerbation of psoriasis vulgaris. Hautarzt 41 (1990) 506-508 (in German).
18. Ito T., and Furukawa F. Psoriasis guttate acuta triggered by varicella zoster virus infection. Eur J Dermatol 10 (2000) 226-227
19. Asadullah K., Prosch S., Audring H., et al. A high prevalence of cytomegalovirus antigenaemia in patients with moderate to severe chronic plaque psoriasis: an association with systemic tumour necrosis factor alpha overexpression. Br J Dermatol 141 (1999) 94-102
20. Yazici A.C., Aslan G., Baz K., et al. A high prevalence of parvovirus B19 DNA in patients with psoriasis. Arch Dermatol Res 298 (2006) 231-235
21. Moles J.P., Tesniere A., and Guilhou J.J. A new endogenous retroviral sequence is expressed in skin of patients with psoriasis. Br J Dermatol 153 (2005) 83-89
22. Weissenborn S.J., Hopfl R., Weber F., Smola H., Pfister H.J., and Fuchs P.G. High prevalence of a variety of epidermodysplasia verruciformis-associated human papillomaviruses in psoriatic skin of patients treated or not treated with PUVA. J Invest Dermatol 113 (1999) 122-126
23. Duvic M., Johnson T.M., Rapini R.P., Freese T., Brewton G., and Rios A. Acquired immunodeficiency syndrome-associated psoriasis and reactive arthritis. Arch Dermatol 123 (1987) 1622-1632
24. Montazeri A., Kanitakis J., and Bazex J. Psoriasis and HIV infection. Int J Dermatol 35 (1996) 475-479
25. Garbe C., Husak R., and Orfanos C.E. HIV-associated dermatoses and their prevalence in 456 HIV-infected patients. Relation to immune status and its importance as a diagnostic marker. Hautarzt 45 (1994) 623-629 (in German).
26. Wolfer L.U., Djemadji-Oudjiel N., Hiletework M., et al. HIV-associated psoriasis. Clinical and histological observations in 36 patients. Hautarzt 49 (1998) 197-202 (in German).
27. Morar N., Dlova N.C., Mosam A., and Aboobaker J. Cutaneous manifestations of HIV in Kwa-Zulu Natal, South Africa. Int J Dermatol 45 (2006) 1006-1007
28. Weitzul S., and Duvic M. HIV-related psoriasis and reactive arthritis. Semin Cutan Med Surg 16 (1997) 213-218
29. Colebunders R., Blot K., Mertens V., and Dockx P. Psoriasis regression in terminal AIDS. Lancet 339 (1992) 1110
30. Reveille J.D., Conant M.A., and Duvic M. Human immunodeficiency virus-associated psoriasis, psoriatic arthritis, and reactive arthritis: a disease continuum?. Arthritis Rheum 33 (1990) 1574-1578
31. Duvic M., Rios A., and Brewton G.W. Remission of AIDS-associated psoriasis with zidovudine. Lancet 2 (1987) 627
32. Obuch M.L., Maurer T.A., Becker B., and Berger T.G. Psoriasis and human immunodeficiency virus infection. J Am Acad Dermatol 27 (1992) 667-673
33. Gupta A.K., Ellis C.N., Nickoloff B.J., et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses: a clinical and immunopathologic analysis. Arch Dermatol 126 (1990) 339-350
34. Klein S.A., Dobmeyer J.M., Dobmeyer T.S., et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS 11 (1997) 1111-1118
35. Austin L.M., Coven T.R., Bhardwaj N., Steinman R., and Krueger J.G. Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis. J Cutan Pathol 25 (1998) 79-88
36. Vissers W.H., Arndtz C.H., Muys L., Van Erp P.E., de Jong E.M., and van de Kerkhof P.C. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol 150 (2004) 852-859
37. Baker B.S., Griffiths C.E., Lambert S., et al. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J Dermatol 116 (1987) 503-510
38. Roederer M., Dubs J.G., Anderson M.T., Raju P.A., Herzenberg L.A., and Herzenberg L.A. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 95 (1995) 2061-2066
39. Fife D.J., Waller J.M., Jeffes E.W., and Koo J.Y. Unraveling the paradoxes of HIV-associated psoriasis: a review of T-cell subsets and cytokine profiles. Dermatol Online J 13 (2007) 4
40. Arnett F.C., Reveille J.D., and Duvic M. Psoriasis and psoriatic arthritis associated with human immunodeficiency virus infection. Rheum Dis Clin North Am 17 (1991) 59-78
41. Duvic M. Immunology of AIDS related to psoriasis. J Invest Dermatol 95 (1990) 38S-40S
42. Fuchs D., Hausen A., Reibnegger G., Werner E.R., Dierich M.P., and Wachter H. Psoriasis, gamma-interferon, and the acquired immunodeficiency syndrome. Ann Intern Med 106 (1987) 165
43. Fuchs D., Hausen A., Reibnegger G., et al. Interferon-gamma concentrations are increased in sera from individuals infected with human immunodeficiency virus type 1. J Acquir Immune Defic Syndr 2 (1989) 158-162
44. Smoller B.R., McNutt N.S., Gray M.H., Krueger J., Hsu A., and Gottlieb A.B. Detection of the interferon-gamma-induced protein 10 in psoriasiform dermatitis of acquired immunodeficiency syndrome. Arch Dermatol 126 (1990) 1457-1461
45. Mahoney S.E., Duvic M., Nickoloff B.J., et al. Human immunodeficiency virus (HIV) transcripts identified in HIV-related psoriasis and Kaposi's sarcoma lesions. J Clin Invest 88 (1991) 174-185
46. Silvestris F., Williams Jr. R.C., and Dammacco F. Autoreactivity in HIV-1 infection: the role of molecular mimicry. Clin Immunol Immunopathol 75 (1995) 197-205
47. Torres B.A., and Johnson H.M. Identification of an HIV-1 Nef peptide that binds to HLA class II antigens. Biochem Biophys Res Commun 200 (1994) 1059-1065
48. Leung D.Y., Walsh P., Giorno R., and Norris D.A. A potential role for superantigens in the pathogenesis of psoriasis. J Invest Dermatol 100 (1993) 225-228
49. Merino E., Torrux D., Boix V., and Portilla J. Improvement of severe psoriasis in a HIV(+) patient. An Med Interna 17 (2000) 52 (in Spanish).
50. Ghoreschi K., Weigert C., and Rocken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 25 (2007) 574-580
51. Ochs H.D., Oukka M., and Torgerson T.R. TH17 cells and regulatory T cells in primary immunodeficiency diseases. J Allergy Clin Immunol 123 (2009) 977-983
52. Ndhlovu L.C., Chapman J.M., Jha A.R., et al. Suppression of HIV-1 plasma viral load below detection preserves IL-17 producing T cells in HIV-1 infection. AIDS 22 (2008) 990-992
53. Leung D.Y., Gately M., Trumble A., Ferguson-Darnell B., Schlievert P.M., and Picker L.J. Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin 12 production. J Exp Med 181 (1995) 747-753
54. Nickoloff B.J., and Wrone-Smith T. Superantigens, autoantigens, and pathogenic T cells in psoriasis. J Invest Dermatol 110 (1998) 459-460
55. Steinman L. Escape from "horror autotoxicus": pathogenesis and treatment of autoimmune disease. Cell 80 (1995) 7-10
56. Stevens R.W., Baltch A.L., Smith R.P., et al. Antibody to human endogenous retrovirus peptide in urine of human immunodeficiency virus type 1-positive patients. Clin Diagn Lab Immunol 6 (1999) 783-786
57. Mallon E., Young D., Bunce M., et al. HLA-Cw*0602 and HIV-associated psoriasis. Br J Dermatol 139 (1998) 527-533
58. Morar N., Dlova N., Gupta A.K., Naidoo D.K., Aboobaker J., and Ramdial P.K. Erythroderma: a comparison between HIV positive and negative patients. Int J Dermatol 38 (1999) 895-900
59. Pillai S., and DiPaolo F. Bilateral panuveitis, sebopsoriasis, and secondary syphilis in a patient with acquired immunodeficiency syndrome. Am J Ophthalmol 114 (1992) 773-775
60. Faergemann J. Treatment of sebopsoriasis with itraconazole. Mykosen 28 (1985) 612-618
61. Doring H.F. Treatment of sebopsoriasis-a clinical trial: an etiological approach. Dermatologica 169 (1984) 125-133
62. Keat A., and Rowe I. Reactive arthritis and associated arthritides. Rheum Dis Clin North Am 17 (1991) 25-42
63. Schlesinger I., Oelrich D.M., and Tyring S.K. Crusted (Norwegian) scabies in patients with AIDS: the range of clinical presentations. South Med J 87 (1994) 352-356
64. Grinspan D., Blanco G.F., Aguero S., Bianchi O., and Stringa S. Ectopic geographic tongue and AIDS. Int J Dermatol 29 (1990) 113-116
65. Sadick N.S., McNutt N.S., and Kaplan M.H. Papulosquamous dermatoses of AIDS. J Am Acad Dermatol 22 (1990) 1270-1277
66. Horn T.D., Herzberg G.Z., and Hood A.F. Characterization of the dermal infiltrate in human immunodeficiency virus-infected patients with psoriasis. Arch Dermatol 126 (1990) 1462-1465
67. Menter A., and Griffiths C.E. Current and future management of psoriasis. Lancet 370 (2007) 272-284
68. Breuer-McHam J., Marshall G., Adu-Oppong A., et al. Alterations in HIV expression in AIDS patients with psoriasis or pruritus treated with phototherapy. J Am Acad Dermatol 40 (1999) 48-60
69. Akaraphanth R., and Lim H.W. HIV, UV and immunosuppression. Photodermatol Photoimmunol Photomed 15 (1999) 28-31
70. Meola T., Soter N.A., Ostreicher R., Sanchez M., and Moy J.A. The safety of UVB phototherapy in patients with HIV infection. J Am Acad Dermatol 29 (1993) 216-220
71. Lim H.W., Vallurupalli S., Meola T., and Soter N.A. UVB phototherapy is an effective treatment for pruritus in patients infected with HIV. J Am Acad Dermatol 37 (1997) 414-417
72. Houpt K.R., Beer J.Z., Horn T.D., Moy J.A., Zmudzka B.Z., and Cruz Jr. P.D. Ultraviolet therapy of HIV-infected individuals: a panel discussion. Semin Cutan Med Surg 16 (1997) 241-245
73. Zancanaro P.C., McGirt L.Y., Mamelak A.J., Nguyen R.H., and Martins C.R. Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. J Am Acad Dermatol 54 (2006) 581-588
74. Stern R.S., and Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 91 (1988) 120-124
75. Stern R.S. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 44 (2001) 755-761
76. In: Bunker C.B., and Gotch F. (Eds). AIDS and the skin. 7th edn. (2004), Blackwell Science Ltd, Oxford
77. Wilkins K., Turner R., Dolev J.C., LeBoit P.E., Berger T.G., and Maurer T.A. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol 54 (2006) 189-206
78. Menon K., Van Voorhees A.S., Bebo Jr. B.F., et al. Psoriasis in patients with HIV infection: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 62 (2010) 291-299
79. Buccheri L., Katchen B.R., Karter A.J., and Cohen S.R. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol 133 (1997) 711-715
80. Blanche P. Acitretin and AIDS-related Reiter's disease. Clin Exp Rheumatol 17 (1999) 105-106
81. Mallon E., and Bunker C.B. HIV-associated psoriasis. AIDS Patient Care STDS 14 (2000) 239-246
82. Garcia-Silva J., Almagro M., Pena-Penabad C., and Fonseca E. Indinavir-induced retinoid-like effects: incidence, clinical features and management. Drug Saf 25 (2002) 993-1003
83. Masson C., Chennebault J.M., and Leclech C. Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis?. J Rheumatol 22 (1995) 2191
84. Maurer T.A., Zackheim H.S., Tuffanelli L., and Berger T.G. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol 31 (1994) 372-375
85. Jacobson S.K., Calne R.Y., and Wreghitt T.G. Outcome of HIV infection in transplant patient on cyclosporin. Lancet 337 (1991) 794
86. Allen B.R. Use of cyclosporin for psoriasis in HIV-positive patient. Lancet 339 (1992) 686
87. Weber J., and Galpin S. HIV results in the frame: cyclosporin A. Nature 375 (1995) 198
88. Linardaki G., Katsarou O., Ioannidou P., Karafoulidou A., and Boki K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 34 (2007) 1353-1355
89. Frassetto L., Baluom M., Jacobsen W., et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 80 (2005) 13-17
90. Forman S.B., Higginson R., and Garrett A.B. Psoriasis and psoriatic arthritis in a patient with HIV: response to mycophenolate mofetil treatment. J Drugs Dermatol 7 (2008) 972-973
91. Hast R., Bernell P., and Hansson M. Cimetidine as an immune response modifier. Med Oncol Tumor Pharmacother 6 (1989) 111-113
92. Urrea A.A., Velez G.M., Nogues A.E., and Camarasa J.G. Psoriasis in an HIV-positive patient treated with cimetidine. Dermatology 191 (1995) 77
93. Stashower M.E., Yeager J.K., Smith K.J., Skelton H.G., and Wagner K.F. Cimetidine as therapy for treatment-resistant psoriasis in a patient with acquired immunodeficiency syndrome. Arch Dermatol 129 (1993) 848-850
94. Smith K.C. Ranitidine useful in the management of psoriasis in a patient with acquired immunodeficiency syndrome. Int J Dermatol 33 (1994) 220-221
95. Smith K.J., and Skelton H.G. Accidental success with carbamazepine for psoriatic erythroderma. N Engl J Med 335 (1996) 1999-2000
96. Rosenberg E.W., Skinner Jr. R.B., and Noah P.W. AIDS and psoriasis. Int J Dermatol 30 (1991) 449
97. Namazi M.R. Nicotinamide: a potential addition to the anti-psoriatic weaponry. Faseb J 17 (2003) 1377-1379
98. Diez F., del Hoyo M., and Serrano S. Zidovudine treatment of psoriasis associated with acquired immunodeficiency syndrome. J Am Acad Dermatol 22 (1990) 146-147
99. Duvic M., Crane M.M., Conant M., Mahoney S.E., Reveille J.D., and Lehrman S.N. Zidovudine improves psoriasis in human immunodeficiency virus-positive males. Arch Dermatol 130 (1994) 447-451
100. Ruzicka T., Froschl M., Hohenleutner U., Holzmann H., and Braun-Falco O. Treatment of HIV-induced retinoid-resistant psoriasis with zidovudine. Lancet 2 (1987) 1469-1470
101. Townsend B.L., Cohen P.R., and Duvic M. Zidovudine for the treatment of HIV-negative patients with psoriasis: a pilot study. J Am Acad Dermatol 32 (1995) 994-999
102. Fischer T., Schworer H., Vente C., Reich K., and Ramadori G. Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy. AIDS 13 (1999) 628-629
103. De Socio G.V.L., Simonetti S., and Stagni G. Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy. Scand J Infect Dis 38 (2006) 74-75
104. Bartke U., Venten I., Kreuter A., Gubbay S., Altmeyer P., and Brockmeyer N.H. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br J Dermatol 150 (2004) 784-786
105. Butera S.T., Roberts B.D., and Folks T.M. Ligand passing by the p75 tumour necrosis factor receptor enhances HIV-1 activation. Cytokine 8 (1996) 745-750
106. Aboulafia D.M., Bundow D., Wilske K., and Ochs U.I. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 75 (2000) 1093-1098
107. Mikhail M., Weinberg J.M., and Smith B.L. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Arch Dermatol 144 (2008) 453-456
108. Cavazzana I., Ceribelli A., Cattaneo R., and Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 8 (2008) 104-106
109. Ting P.T., and Koo J.Y. Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int J Dermatol 45 (2006) 689-692
110. Sellam J., Bouvard B., Masson C., et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine 74 (2007) 197-200
111. Gill H., and Majithia V. Successful use of infliximab in the treatment of reactive arthritis: a case report and discussion. Clin Rheumatol 27 (2008) 121-123